A double-blind clinical trial is a study in which neither the participants nor the study staff working with them know who is receiving the investigational treatment and who is receiving a placebo or comparison treatment. Participants are placed into groups by randomization, which means chance decides each assignment. Together, randomization and blinding keep expectations from shaping the results, so the study measures what the treatment actually does.
If you’re participating in a clinical trial for the first time, both terms will appear in your consent form. Here’s what they mean for you.
Key takeaways
- Randomization assigns participants to study groups by chance, using a schedule generated before the study starts. No one on the study team picks your group.
- In a double-blind clinical trial, you and the staff assessing you don’t know your assignment until the study ends, unless it’s needed for your safety.
- Blinding matters because expectations can change how people report symptoms and how staff judge results.
- Not every study is blinded. In an open-label study, everyone knows which treatment each participant receives.
- In a medical emergency, the investigator can find out your assignment quickly so you get the right care.
What does randomization mean in a clinical trial?
Randomization means each participant is assigned to a study group by chance. A computer generates the assignment list before enrollment begins, and neither you nor the investigator chooses where you land.
Groups don’t always have equal odds. Some studies use a 1:1 ratio, an even split, while others use 2:1, so two of every three participants receive the investigational treatment. Your consent form should tell you your chances of being in each group, which is one reason to read it closely during the informed consent process.
Why do clinical trials use randomization?
Randomization keeps the groups comparable. When chance decides who goes where, factors like age, health history, and lifestyle tend to balance out across groups, including factors no one thought to measure. Any difference in results is then more likely to come from the treatment itself.
FDA builds this into its standards for evidence. Its regulation on adequate and well-controlled studies calls for an assignment method that minimizes bias and for steps, such as blinding, that reduce bias among participants, observers, and the people analyzing the data.
What are the types of blinding?
Blinding, also called masking, means keeping group assignments hidden from some or all of the people involved in a study. Studies describe it by who doesn’t know.
| Design | Do participants know their group? | Does the study team know? | Where it’s often used |
|---|---|---|---|
| Open-label | Yes | Yes | Studies where blinding isn’t practical, such as comparing a pill with an infusion, and many extension studies |
| Single-blind | No | Yes | Studies where the treatment can be hidden from participants but not from staff |
| Double-blind | No | No | Many placebo-controlled studies testing whether a treatment works |
| Triple-blind | No | No, and neither do the people analyzing the data | Studies that add another layer of protection against bias |
Sponsors don’t always use these labels the same way, so ask the study team exactly who will and won’t know your assignment.
Why does blinding matter in a double-blind clinical trial?
Expectations are powerful. People who know they’re getting a new treatment may feel better, or notice side effects more, simply because they expect to. That’s the placebo effect, and this guide to the placebo effect in clinical trials explains how researchers account for it.
Staff are human too. An investigator who knows a participant’s group might rate symptoms a little more hopefully or watch more closely for certain side effects. Keeping both sides blind takes that influence out of the measurements.
How do studies keep the blind?
The study treatment and its placebo or comparison are made to look alike. Pills match in size, color, and taste, and injections come in identical packaging. When two treatments can’t be made to match, some studies use a “double-dummy” design, where each participant takes one active product and one placebo that looks like the other treatment.
Some studies also have an unblinded pharmacist or staff member who prepares the study product but plays no part in assessing participants. Everyone else on the team stays blind.
What happens if you need emergency care during a blinded study?
Your safety comes first. Blinded studies include a procedure for “breaking the blind,” which lets the investigator find out your assignment quickly when your care depends on it. It’s one of the patient safety protections in clinical research that are planned before a study opens.
Carry the study contact card you’re given and show it at any emergency room or doctor’s office. It tells other providers you’re in a study and gives them a number to call.
Will you find out which group you were in?
Usually, but not right away. Assignments generally stay hidden until the whole study ends and the data is finalized, which can be months after your last visit. Some sponsors share each participant’s assignment afterward, while others share only overall results, so ask at the start how and when you’ll learn yours.
Randomized, double-blind designs are especially common in Phase 2 and Phase 3 studies, which test whether a treatment works and how it compares with existing options. This overview of clinical trial phases shows where each design tends to fit.
Have questions about how a specific study is designed?
Randomization and blinding can sound clinical on paper. Before you sign anything, the South Florida Clinical Research Institute study team explains how assignment works for that specific study and answers your questions, including your chances of receiving a placebo.
Interested in participating in a clinical trial? View current studies or see if you qualify.
Frequently asked questions
Are all clinical trials double-blind?
No. Many studies are open-label or single-blind, depending on what’s being tested and whether blinding is practical. Your consent form names the design, and the study team can explain why it was chosen.
Does getting a placebo mean I go without treatment?
Not necessarily. In many studies, the placebo or study drug is added on top of your usual treatment, so you keep your standard care. If a study asks you to pause a treatment, the consent form explains why and how you’ll be monitored.
Can I guess which group I’m in?
Some people try, based on side effects or how they feel, but those guesses aren’t reliable. Acting on a guess, such as skipping doses, can affect your safety and the results, so keep following the study plan and report any changes to the team.
Can I leave a double-blind study if I’m unhappy with my progress?
Yes. Taking part is voluntary, and you can stop at any time. Talk with the investigator first, since some treatments need to be stopped gradually. Here’s what to know about your right to withdraw from a clinical trial.